Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Depreciation & Amortization - Total (2017 - 2025)

Historic Depreciation & Amortization - Total for Vanda Pharmaceuticals (VNDA) over the last 9 years, with Q4 2025 value amounting to $304000.0.

  • Vanda Pharmaceuticals' Depreciation & Amortization - Total rose 1603.05% to $304000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 million, marking a year-over-year increase of 2255.56%. This contributed to the annual value of $1.1 million for FY2025, which is 2255.56% up from last year.
  • Vanda Pharmaceuticals' Depreciation & Amortization - Total amounted to $304000.0 in Q4 2025, which was up 1603.05% from $301000.0 recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Depreciation & Amortization - Total ranged from a high of $374000.0 in Q4 2021 and a low of $200000.0 during Q3 2023
  • Moreover, its 5-year median value for Depreciation & Amortization - Total was $287500.0 (2022), whereas its average is $277000.0.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Depreciation & Amortization - Total crashed by 3311.04% in 2023, and later surged by 3935.19% in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Depreciation & Amortization - Total stood at $374000.0 in 2021, then dropped by 24.06% to $284000.0 in 2022, then decreased by 27.82% to $205000.0 in 2023, then rose by 27.8% to $262000.0 in 2024, then increased by 16.03% to $304000.0 in 2025.
  • Its last three reported values are $304000.0 in Q4 2025, $301000.0 for Q3 2025, and $267000.0 during Q2 2025.